A study has found that adults with obesity taking GLP-1 receptor agonists may face significantly lower risk of developing certain cancers.
The cohort study was led by researchers from the Indiana School of Medicine in Indianapolis and the University of Florida College of Medicine in Gainesville and published Aug. 21 in JAMA Oncology. It used data from the OneFlorida+ networks and analyzed electronic health records from 86,632 individuals between 2014 and 2024. Researchers compared 43,317 GLP-1 receptor agonist users to 43,315 nonusers and found a 17% reduction in overall cancer risks in individuals taking the drug.
Specifically, GLP-1 use was linked to lower risks of endometrial, ovarian and meningioma cancers.
However, the study found a nonsignificant increase in kidney cancer risk among users.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
